- (PLX AI) - Novo Nordisk is poised for strong growth next year, analysts at Bank of America said, reiterating a buy recommendation on the stock.
- • Novo issued a Q3 pre-release showing a big beat of consensus as well as guidance upgrade for this year
- • Details have yet to be revealed, but the full report this week likely will show stronger-than-expected sales of Novo's new obesity drug, Wegovy, BofA said
- • If the early trajectory of Wegovy continues, Novo is set for substantial upgrades next year, and has the potential to be the most compelling launch story in EU pharma, BofA said
- • Price target maintained at DKK 735
© 2021 PLX AI
